These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 10598250)

  • 1. [Antithrombotics and interventional cardiology].
    Collet JP; Montalescot G
    Arch Mal Coeur Vaiss; 1999 Nov; 92(11 Suppl):1667-79. PubMed ID: 10598250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results.
    Popma JJ; Satler LF
    J Invasive Cardiol; 1994; 6 Suppl A():19A-28A; discussion 45A-50A. PubMed ID: 10155090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA
    Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.
    Ibbotson T; McGavin JK; Goa KL
    Am J Cardiovasc Drugs; 2003; 3(5):381-6. PubMed ID: 14728074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation.
    Ibbotson T; McGavin JK; Goa KL
    Drugs; 2003; 63(11):1121-63. PubMed ID: 12749745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiplatelet therapy in therapy-resistant unstable angina. A pilot study with REO PRO (c7E3).
    van den Brand MJ; Simoons ML; de Boer MJ; van Miltenburg A; van der Wieken LR; de Feyter PJ
    Eur Heart J; 1995 Nov; 16 Suppl L():36-42. PubMed ID: 8869017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease.
    Berkowitz SD
    Haemostasis; 2000; 30 Suppl 3():27-43. PubMed ID: 11182626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A risk-benefit assessment of abciximab in angioplasty.
    Kleiman NS
    Drug Saf; 1999 Jan; 20(1):43-57. PubMed ID: 9935276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The anti-GPIIb-IIIa agents: fundamental and clinical aspects.
    Coller BS; Anderson KM; Weisman HF
    Haemostasis; 1996 Oct; 26 Suppl 4():285-93. PubMed ID: 8979134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of new pharmacologic agents in the treatment of acute thrombotic syndromes.
    Stone GW
    Am J Cardiol; 1999 May; 83(9A):16E-20E. PubMed ID: 10357577
    [No Abstract]   [Full Text] [Related]  

  • 11. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
    N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Medico-economic evaluation of abciximab].
    Le Pen C; Bonastre J; Pinton P
    Ann Cardiol Angeiol (Paris); 1999 Jan; 48(1):80-6. PubMed ID: 12555363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of abciximab (c7E3 Fab, ReoPro) as an adjunct to balloon angioplasty.
    McGregor M; Brophy JM
    Can J Cardiol; 1999 Feb; 15(2):201-7. PubMed ID: 10079780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.
    EPIC Investigators
    N Engl J Med; 1994 Apr; 330(14):956-61. PubMed ID: 8121459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Abciximab in the treatment of acute coronary syndromes by angioplasty and stents].
    Pinton P
    Therapie; 1998; 53(4):341-7. PubMed ID: 9806003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
    EPILOG Investigators
    N Engl J Med; 1997 Jun; 336(24):1689-96. PubMed ID: 9182212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventing coronary restenosis and complications.
    Holmes DR
    N Engl J Med; 1997 Jun; 336(24):1748-9. PubMed ID: 9180094
    [No Abstract]   [Full Text] [Related]  

  • 19. Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease.
    Faulds D; Sorkin EM
    Drugs; 1994 Oct; 48(4):583-98. PubMed ID: 7528131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New antiplatelet agents: platelet GPIIb/IIIa antagonists.
    Coller BS; Anderson K; Weisman HF
    Thromb Haemost; 1995 Jul; 74(1):302-8. PubMed ID: 8578476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.